文献速递精神分裂症与精神病性障碍

LB-102治疗成人急性精神分裂症的疗效与安全性随机临床试验

Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

这项在美国开展的多中心、双盲、安慰剂对照2期随机临床试验(NOVA1)纳入359例急性精神分裂症成人患者,评估LB-102 50mg、75mg、100mg的疗效与安全性。结果显示LB-102 50mg和75mg在第4周PANSS总分较基线的改善上显著优于安慰剂,100mg也显示显著性;治疗中出现的不良事件在安慰剂组为56%,50mg组69%,75mg组57%,100mg组75%。

要点

  • LB-102 50mg和75mg在第4周PANSS总分改善上显著优于安慰剂。
  • LB-102 100mg也显示显著改善,但样本量较小(n=36)。
  • 治疗中出现的不良事件发生率安慰剂组56%,50mg组69%,75mg组57%,100mg组75%。

核心结论

  • LB-102对成人急性精神分裂症治疗显示出疗效和安全性。

研究设计与样本

  • 美国多中心、双盲、安慰剂对照、2期随机临床试验(NOVA1),2023年12月至2024年8月开展。
  • 纳入18-55岁精神分裂症成人患者,需因精神病性症状急性加重住院或继续住院,PANSS总分80-120,至少2个关键阳性症状条目评分≥4,CGI-S≥4。
  • 参与者按3:3:3:1随机分配至口服每日一次安慰剂、LB-102 50mg、75mg或100mg。
  • 共359例参与者被随机并纳入安全性和意向治疗人群(安慰剂n=108;50mg n=107;75mg n=108;100mg n=36)。

主要发现

  • 主要终点达标:第4周PANSS总分较基线变化,安慰剂组均值(SE)-9.3(1.08),50mg组-14.3(1.10),P<.001,Hedges g=0.61;75mg组-14.0(1.11),P=.002,Hedges g=0.41。
  • LB-102 100mg组第4周PANSS总分较基线变化均值(SE)-16.1(1.91),名义P=.002,Hedges g=0.83。
  • 治疗中出现的不良事件:安慰剂组60例(56%),50mg组74例(69%),75mg组62例(57%),100mg组27例(75%)。
  • 导致退出的治疗中出现的不良事件共10例(安慰剂2例;50mg 2例;75mg 3例;100mg 3例),严重治疗中出现的不良事件5例(安慰剂2例[包括1例死亡];每个LB-102组1例)。

关键数值与推荐

  • 主要终点为第4周PANSS总分较基线变化,对LB-102 50mg和75mg vs 安慰剂采用Hochberg多重性校正。
  • 次要疗效终点包括第4周CGI-S评分变化、CGI-S应答、PANSS子量表评分、PANSS Marder因子评分及PANSS应答≥20%。
  • 安全性终点包括治疗中出现的不良事件。

临床怎么用

  • LB-102 50mg和75mg每日一次口服可显著改善急性精神分裂症患者的PANSS总分。
  • 使用LB-102时需监测治疗中出现的不良事件,50mg组和100mg组不良事件发生率高于安慰剂组。

局限性

  • 100mg组样本量较小(n=36),其显著性为名义P值。
  • 研究为2期试验,样本量有限,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: LB-102 (N-methyl amisulpride) is a novel benzamide under investigation for the treatment of schizophrenia. OBJECTIVE: To evaluate the efficacy and safety of LB-102 in acute schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: This US-based, multicenter, double-blind, placebo-controlled, phase 2 randomized clinical trial (NOVA1) conducted from December 2023 to August 2024 comprised an inpatient screening period (≤14 days), 28-day inpatient treatment period, 5-day inpatient stabilization period, and outpatient safety follow-up visit approximately 2 weeks after the treatment period end. Eligible participants were adults (aged 18-55 years) with schizophrenia who required hospitalization or continued hospitalization for an acute exacerbation of psychotic symptoms and had a Positive and Negative Syndrome Scale (PANSS) total score of 80 to 120, PANSS Positive Symptoms subscale item score of 4 or greater on 2 or more key items, and a Clinical Global Impressions-Severity of Illness scale (CGI-S) score of 4 or greater at screening and baseline. INTERVENTIONS: Participants were randomized (3:3:3:1) to oral once-daily placebo, LB-102 50 mg, 75 mg, or 100 mg. MAIN OUTCOMES AND MEASURES: The primary end point was change from baseline to week 4 in PANSS total score (Hochberg multiplicity correction for LB-102 50 mg and 75 mg vs placebo). Secondary efficacy end points included changes from baseline to week 4 in CGI-S score, CGI-S response, PANSS subscale scores, PANSS Marder factor scores, and 20% or greater PANSS response. Safety and tolerability end points included treatment-emergent adverse effects (TEAEs). RESULTS: A total of 359 participants (mean [SD] age, 39.1 [9.3] years; 290 male [80.8%]; mean baseline PANSS total score = approximately 94 across groups) were randomized and included in the safety and intention-to-treat populations (placebo, n = 108; 50 mg, n = 107; 75 mg, n = 108; 100 mg, n = 36). The trial met the primary end point: LB-102 50 mg and 75 mg, were statistically superior to placebo in change from baseline to week 4 in PANSS total score (mean [SE], placebo, -9.3 [1.08]; 50 mg, -14.3 [1.10], P < .001; Hedges g = 0.61; 75 mg, -14.0 [1.11], P = .002; Hedges g = 0.41); LB-102 100 mg, also showed significance (mean [SE], -16.1 [1.91]; nominal P = .002; Hedges g = 0.83). TEAEs were reported in 60 participants (56%) in the placebo group, 74 (69%) in the group receiving 50 mg, 62 (57%) in the group receiving 75 mg, and 27 (75%) in the group receiving 100 mg. Ten participants reported TEAEs leading to withdrawal (placebo, n = 2; 50 mg, n = 2; 75 mg, n = 3; 100 mg, n = 3) with 5 serious TEAEs (placebo, n = 2 [including 1 death]; each LB-102 arm, n = 1). CONCLUSIONS AND RELEVANCE: This randomized clinical trial provided rigorous evidence demonstrating the efficacy and safety of LB-102 for the treatment of adults with acute schizophrenia. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06179108.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Eramo A, Correll CU, Walling DP, et al. Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 42018313. doi:10.1001/jamapsychiatry.2026.0428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。